Department of Physiology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville, Durban, South Africa.
Department of Pharmacy and Pharmacology, Rhodes University, Grahamstown, South Africa.
Oxid Med Cell Longev. 2020 Jun 22;2020:2978340. doi: 10.1155/2020/2978340. eCollection 2020.
Recently, studies have shown that renal dysfunction is associated not only with overt diabetes but also with the preceding stage known as prediabetes. Diet and pharmacological interventions are the therapeutic approaches to managing prediabetes, but the compliance in combining the two interventions is low. Hence, the efficacy of pharmacological intervention is reduced without diet modification. In our previous study, we established that bredemolic acid (BA) ameliorated glucose homeostasis via increased GLUT 4 expression in the skeletal muscle of prediabetic rats in the absence of diet intervention. However, the effects of bredemolic acid on renal function in prediabetic condition are unknown. Therefore, this study was aimed at investigating the ameliorative effects of bredemolic acid on renal dysfunction in a diet-induced prediabetic rat model. Thirty-six Sprague-Dawley male rats (150-180 g) were divided into two groups: the nonprediabetic ( = 6) and prediabetic ( = 30) groups which were fed normal diet (ND) and high-fat high-carbohydrate (HFHC) diet, respectively, for 20 weeks. After the 20 week, the prediabetic groups were subdivided into prediabetic control (PD) and 4 other prediabetic groups which were treated with either BA (80 mg/kg) or metformin (MET, 500 mg/kg) for further 12 weeks (21 to 32). Plasma, urine, and kidney samples were collected for biochemical analysis. The untreated prediabetic (PD) rats presented increased fluid intake and urine output; increased creatinine, urea, and uric acid plasma concentrations; albuminuria; proteinuria; sodium retention; potassium loss; increased aldosterone and kidney injury molecule (KIM-1) concentration; and increased urinary podocin mRNA expression. However, BA administration attenuated the renal markers and oxidative stress and decreased the urinary podocin mRNA expression. In conclusion, BA administration, regardless of diet modification, attenuates renal dysfunction in an experimentally induced prediabetic state.
最近的研究表明,肾功能障碍不仅与显性糖尿病有关,还与先前的糖尿病前期阶段有关。饮食和药物干预是管理糖尿病前期的治疗方法,但同时进行这两种干预的依从性较低。因此,在不改变饮食的情况下,药物干预的效果会降低。在我们之前的研究中,我们发现 bredemolic 酸(BA)通过增加糖尿病前期大鼠骨骼肌中的 GLUT4 表达来改善葡萄糖稳态,而无需饮食干预。然而,bredemolic 酸对糖尿病前期状态下肾功能的影响尚不清楚。因此,本研究旨在研究 bredemolic 酸对饮食诱导的糖尿病前期大鼠模型中肾功能障碍的改善作用。36 只 Sprague-Dawley 雄性大鼠(150-180g)分为两组:非糖尿病组(n=6)和糖尿病前期组(n=30),分别给予正常饮食(ND)和高脂肪高碳水化合物饮食(HFHC),共 20 周。20 周后,糖尿病前期组再分为糖尿病前期对照组(PD)和另外 4 个糖尿病前期组,分别用 BA(80mg/kg)或二甲双胍(MET,500mg/kg)治疗 12 周(21-32 周)。收集血浆、尿液和肾脏样本进行生化分析。未经治疗的糖尿病前期大鼠(PD)表现出增加的液体摄入和尿量;增加的肌酐、尿素和尿酸血浆浓度;白蛋白尿;蛋白尿;钠潴留;钾丢失;醛固酮和肾脏损伤分子(KIM-1)浓度增加;以及尿 podocin mRNA 表达增加。然而,BA 给药可减轻肾脏标志物和氧化应激,并降低尿 podocin mRNA 表达。总之,BA 给药,无论是否改变饮食,均可减轻实验诱导的糖尿病前期状态下的肾功能障碍。